VBI Vaccines, Inc. - Ordinary Shares (VBIV): Price and Financial Metrics

VBI Vaccines, Inc. - Ordinary Shares (VBIV): $0.60

0.02 (+3.75%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add VBIV to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#190 of 348

in industry

VBIV Price/Volume Stats

Current price $0.60 52-week high $3.47
Prev. close $0.57 52-week low $0.45
Day low $0.58 Volume 13,549
Day high $0.60 Avg. volume 291,315
50-day MA $0.61 Dividend yield N/A
200-day MA $0.64 Market Cap 17.07M

VBIV Stock Price Chart Interactive Chart >


VBI Vaccines, Inc. - Ordinary Shares (VBIV) Company Bio


VBI Vaccines Inc. develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.


VBIV Latest News Stream


Event/Time News Detail
Loading, please wait...

VBIV Latest Social Stream


Loading social stream, please wait...

View Full VBIV Social Stream

Latest VBIV News From Around the Web

Below are the latest news stories about VBI VACCINES INC that investors may wish to consider to help them evaluate VBIV as an investment opportunity.

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

CAMBRIDGE, Mass., November 20, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients, were highlighted in a poster presentation at the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SN

Yahoo | November 20, 2023

VBI Vaccines Reports Third Quarter 2023 Financial Results

CAMBRIDGE, Mass., November 14, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023.

Yahoo | November 14, 2023

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

CAMBRIDGE, Mass., October 26, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company’s current proprietary eVLP technology by coding the particles in messenger RNA (mRNA). In preclinical studies, VBI’s new mRNA-launched eVLP (MLE) technology has dem

Yahoo | October 26, 2023

VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern

CAMBRIDGE, Mass., September 27, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data from the Phase 1 clinical study of its multivalent pan-coronavirus vaccine candidate, VBI-2901, which expresses the ancestral COVID-19, SARS, and MERS spike antigens. The Phase 1 clinical study enrolled 101 adults, aged 18-64 years who had received either two or three doses of a

Yahoo | September 27, 2023

VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

CAMBRIDGE, Mass., September 07, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the first patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM). The study will assess the safety, tolerability, tumor response rates, and survival following tre

Yahoo | September 7, 2023

Read More 'VBIV' Stories Here

VBIV Price Returns

1-mo -4.76%
3-mo 4.35%
6-mo 11.11%
1-year N/A
3-year -99.49%
5-year -97.90%
YTD 2.13%
2023 -94.99%
2022 -83.29%
2021 -14.91%
2020 99.28%
2019 -13.75%

Continue Researching VBIV

Here are a few links from around the web to help you further your research on VBI Vaccines Inc's stock as an investment opportunity:

VBI Vaccines Inc (VBIV) Stock Price | Nasdaq
VBI Vaccines Inc (VBIV) Stock Quote, History and News - Yahoo Finance
VBI Vaccines Inc (VBIV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!